GlassScriptPhysician profile
Robert F Ryhal
NPI 1902469026
$1,373.31
in general payments reported to CMS, 2019-2025
19 companies · $826 in 2025
The $826 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $42.07 · 2024: $505 · 2025: $826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,371 · Education: $2.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,370.93 |
| Education | $2.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $244.00 | 2024-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $203.03 | 2024-2025 | Jynarque, Voyxact |
| Amgen INC. | $158.75 | 2024-2025 | Krystexxa, Tavneos, Uplizna |
| Bayer Healthcare Pharmaceuticals INC. | $107.19 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.95 | 2024-2025 | Jardiance |
| Travere Therapeutics, INC. | $92.24 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $85.05 | 2024-2025 | |
| Genentech USA, INC. | $61.38 | 2025 | Gazyva |
| Opko Pharmaceuticals, LLC | $55.85 | 2024 | Rayaldee |
| Ardelyx, INC. | $46.99 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $36.20 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $31.64 | 2025 | Ozempic |
| Calliditas Therapeutics US INC. | $30.64 | 2024 | |
| Aurinia Pharma U.S., INC. | $28.01 | 2023 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $21.87 | 2025 | Terlivaz |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $19.93 | 2024 | Purified Cortrophin Gel |
| Scpharmaceuticals INC. | $19.10 | 2025 | |
| Kyowa Kirin, INC. | $14.43 | 2025 | |
| Vifor Pharma, INC. | $14.06 | 2023 | Veltassa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ryhal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.